AdAPT-001 is under clinical development by EpicentRx and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II drugs for Leiomyosarcoma have a 17% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AdAPT-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AdAPT-001 overview

AdAPT-001 is under development for the treatment of malignant solid tumor, leiomyosarcoma, chondrosarcoma, triple-negative breast cancer, chordoma and liver metastases in metastatic colorectal cancer (mCRC). The therapeutic candidate is a replication competent adenovirus type-5 carrying a TGF-beta trap transgene. It is developed based on Adaptigene oncolytic virus platform. It is administered through intratumor route and hepatic artery infusion. The drug candidate is adenovirus viral vector.

EpicentRx overview

EpicentRx is a biopharmaceutical company that carries out the development of novel therapies aimed at targeting cancer and chronic diseases. The company’s main products include the PRETECT Platform, featuring the Phase 3 investigational product RRx-001, and the AdAPT Platform, with its lead clinical stage candidate AdAPT-001. EpicentRx has developed the proprietary eLoop device, designed for optimized delivery of intravenous treatments. The company’s products are intended for use in the pharmaceutical industry, specifically for the treatment of various forms of cancer and chronic inflammatory diseases. The company operates in the US and China. EpicentRx is headquartered in La Jolla, California, the US.

For a complete picture of AdAPT-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.